Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 316 participants.
Also called NCT01644175
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 316 participants
- Sponsor
- Registry
-
NCT01644175
-
- Other papers using this trial's data
- Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT01644175. Randomized; quadruple masking; primary purpose treatment. Start 2012-07 (registry gives no type); primary completion 2014-04 (actual). Results posted on 2015-11-06.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)
- Condition
- Hypercholesterolemia
- Intervention (Drug)
- Placebo (for alirocumab)
- Intervention (Drug)
- Alirocumab
- Intervention (Drug)
- Lipid-Modifying Therapy (LMT)
- Lead sponsor
- Sanofi
- Collaborator
- Regeneron Pharmaceuticals
Record details
- Record id
cardio:ct-nct01644175- Content hash
516b2a3e8245a9fccba354b114b25ba993dc3bf90dc08100a23d7375bd29fc2b